C-Path Launches Clinical Trial Simulator for Duchenne Muscular Dystrophy Research

TUCSON, Ariz., March 28, 2024 — Critical Path Institute’s (C-Path) Duchenne Regulatory Science Consortium (D-RSC) is excited to announce the launch of a groundbreaking model-based Clinical Trial Simulator (CTS), specifically designed to improve design of efficacy studies for potential therapies for Duchenne muscular dystrophy (DMD). This pioneering Drug Development Tool is set to positively impact the medical research community by significantly optimizing clinical trial design.Continue reading